Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Trametinib is a broad-spectrum anti-cancer drug.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：9
Patients with unresectable or metastatic melanoma with BRAF V600E mutation.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：7
Thrombocytopenia in patients with chronic liver disease and chronic immune disorders.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：17
Cabozantinib has been approved for the treatment of various cancers.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：18
Suitable for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFRT790M mutation positivity.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：0
Treat thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：10
Crizotinib is suitable for the treatment of non-small cell lung cancer.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：4
Finerenone is applicable to chronic kidney disease related to type 2 diabetes.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：17
Mitotane is used for treatment Adrenal cortex carcinoma.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：5
Cibinqo can treat atopic dermatitis.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：4
Broad-spectrum antitumor agents【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：3
KRAS G12C mutation in non-small cell lung cancer and colorectal cancer【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：16
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
